Price movement over the last 24 hours
YieldMax AMD Option Income Strategy ETF vs Moderna, Inc. — how do they compare? YieldMax AMD Option Income Strategy ETF trades at $54.3, while Moderna, Inc. trades at $67.93 (market cap $27.09B). Which is the better fit depends on your goals.
| AMDY | MRNA | |
|---|---|---|
Sector | Income / Options Overlay | Health |
52-Week High | $59.52 | $81.80 |
52-Week Low | $29.80 | $22.36 |
Market Cap | — | $27.09B |
Enterprise Value | — | $23.18B |
Signals from Pluang's Aura AI — not financial advice
AMDY trades at $55.56, up 2.04% today, with a bullish technical signal from moving averages and neutral oscillators. The ETF shows strong weekly dividend distributions but lacks traditional valuation metrics. Recent news highlights its high-yield strategy and associated risks of NAV erosion, with support at $54 and resistance at $56.
The outlook is mixed: high income appeals, but structural risks and analyst caution suggest volatility. Investors must weigh yield sustainability against potential capital depreciation, with entry timing critical for long-term viability.
Moderna (MRNA) trades at $68.27, down 10.83% amid a biotech sell-off, but maintains a bullish technical trend with strong moving averages. Revenue has declined from pandemic peaks to $1.92B in 2025, with net losses widening to -$2.82B, yet recent quarterly EPS beats and pipeline expansions into oncology and flu vaccines fuel optimism. The stock remains volatile, with a consensus price target of $49.00 below the current price, reflecting mixed analyst sentiment.
The outlook hinges on pipeline execution, with EU RSV vaccine contracts and FDA decisions offering upside, but high cash burn and competitive pressures pose risks. Investors face a trade-off between growth potential and profitability challenges, with the stock's 70% monthly surge testing sustainability near-term.
Trailing returns across standard periods
AMDY is an active ETF that seeks to generate weekly income by selling call options on AMD stock. It aims to provide investors with high yield while maintaining exposure to the price movements of Advanced Micro Devices.
Read more on AMDY →Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →